Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES)

Circulation

Volumn 102, Issue 22, 2000, Pages 2700-2706

  Zannad, F ^a   Alla, F ^a   Dousset, B ^a   Perez, A ^a   Pitt, B ^a  

^a Ctr Hospitalier Univ de Nancy   (France)

Author keywords

Collagen; Heart failure; Hormones; Tissue; Trials

Indexed keywords

PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SPIRONOLACTONE;

AGED; ARTICLE; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; EXTRACELLULAR MATRIX; FEMALE; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

EID: 0034727695     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.22.2700     Document Type: Article

References (40)

1. The effect of spironolactone on morbidity and mortality in patients with sever heart failure: Randomized Aldactone Evaluation Study Investigators
2. Aldosterone and spironolactone in heart failure
3. Angiotensin-converting enzyme inhibitor and spitonolactone combination therapy: New objectives in congestive heart failure treatment
4. Aldosterone and heart failure
5. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaidosteronism
6. Antagonism of the renin-angiotensin-aldostemne system and collagen metabolism in cardiac fibroblasts
7. Aldosterone and cardiac fibrosis: In vitro studies
8. Molecular mechanisms of myocardial remodeling
9. Monitoring tissue repair and fibrosis from a distance
10. Abnormalities of the extracellular degradation of collagen type I in essential hypertension
11. Collagen scar formation after acute myocardial infarction: Relationships to infarct size, left ventricular function, and coronary artery patency
12. Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy
13. The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction
14. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis
15. Increased serum concentration of procollagen peptides in essential hypertension: Relation to cardiac alteration
16. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease
17. Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood
18. Immunoassay for intact amino-terminal propeptide of human type I procollagen
19. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen
20. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen
21. Monitoring fibrillar collagen turnover in hypertensive heart disease
22. Serum markers of collagen type I metabolism in spontaneously hypertensive rats
23. Studies on collagen in the experimental myocardial infarction
24. Analysis of healing after myocardial infarction using polarized light microscopy
25. Analysing connective tissue metabolites in human serum: Biochemical, physiological and methodological aspects
26. Serum aminoterminal type III procollagen peptide reflects repair after myocardial infarction
27. Thrombolytic therapy with streptokinase stimulates collagen breakdown
28. Infarct scar: A dynamic tissue
29. The alpha-smooth muscle actin-positive cells in healing human myocardial scars
30. Collagen remodeling after myocardial infarction in the rat heart
31. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: The EPICAL study: Epidemiologie de l'insuffisance cardiaque avancee en lorraine
32. Digoxin in heart failure: Results of the recent Digoxin Investigation Group trial in the context of other treatments for heart failure
33. Matrix metalloproteinases and their inhibitors in connective tissue remodeling
34. Tissue inhibitor of metallo-proteinases (TIMP, aka EPA): Structure, control of expression and biological functions
35. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone
36. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension
37. Mineralocorticoids, hypertension and cardiac fibrosis
38. Mineralocorticoid excess, dietary sodium and myocardial fibrosis
39. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients
40. Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: In vivo and in vitro studies on collagen matrix regulation